PP
Praetego Private Wealth
praetego.com
Website unreachable since Oct 23, 2026
Praetego Inc. develops proprietary small molecules, known as Amadorins, that inhibit glucotoxicity to mitigate the progression of age-related neurodegenerative diseases, particularly Alzheimer's disease. Their lead candidate, PTG-630, has shown preclinical efficacy in reversing cognitive decline and is set to enter clinical trials following a successful Pre-IND meeting.
- Biotechnology
Updated 7 months ago
Funding
Funding rounds are not available yet.
Founders
Product
Features
- Praetego Inc. develops proprietary small molecules, known as Amadorins, that inhibit glucotoxicity to mitigate the progression of age-related neurodegenerative diseases, particularly Alzheimer's disease. Their lead candidate, PTG-630, has shown preclinical efficacy in reversing cognitive decline and is set to enter clinical trials following a successful Pre-IND meeting.